Psychiatric care
could improve in the future thanks to a new push to improve the amount of
research that is carried out on the disease.
The PharmaCog consortium is part of the EU's Innovative Medicines Initiative and
is initially funded for five years with over £23 million and exists to
facilitate the advancement of new Alzheimer's disease drugs.
Global pharmaceutical companies such as GlaxoSmithKline, AstraZeneca and Eli
Lilly are key part of the initiative which also includes 14 academic
establishments across Europe.
Dr Simon Ridley, head of research at Alzheimer's Research UK, stated that the
disease was a major problem in the UK, with 500,000 sufferers living with
symptoms in the country, but until now little funding has been made available
to develop more effective drugs.
"Initiatives such as PharmaCog, which promote collaboration across
countries and research sectors, could provide an excellent way for progress to
be made in developing new treatments to tackle this devastating disease,"
he added.
© Adfero Ltd
Alzheimer's treatment news : 24 February 2012
